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Solid-phase microextraction (SPME) is an approach to sample preparation that has demonstrated 
its appropriateness for isolating/enriching analytes present in complex biofluids with minimum 
sample pre-treatment. Several prior in vitro and in vivo studies have used SPME to monitor the 
concentrations of various drugs and metabolites in blood samples. In this work, we present the 
results of an investigation into how various levels of hematocrit (Hct) affect SPME recoveries. The 
matrices for this study consisted of whole blood samples that had been adjusted at three 
different Hct levels (20%, 45%, and 70%), and the selected model compounds were drugs with 
different physicochemical characteristics (log P range from 0.33 to 6.36). In addition, two 
experimental setups were employed to conduct the extractions: hydrophilic lipophilic balanced 
(HLB) coated SPME devices (HLB-D) at 1500 rpm (vortex agitation), and mixed mode SPME fibres 
(MM-F) at 400 rpm (orbital shaking agitation). Our results demonstrated that the Hct effect in 
SPME is dependent on the analytes of interest, and that different outcomes can be attained by 
altering experimental conditions, such as coating type, convection, and extraction time. 
Interestingly, a target compound’s relative affinity for the matrix components and for the coating 
material proved to be one of the main factors that determine the final effect that different 
erythrocyte levels have on SPME recoveries. Finally, although the Hct content affects each 
analyte differently and the final Hct effect depends on the experimental parameters, matrix 
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Highlights: 
• In this work an investigation into how the hematocrit (Hct) affects SPME recoveries is 
presented. 
•  Our results demonstrated that the Hct effect in SPME is dependent on the analytes, and 
that different outcomes can be attained by altering experimental conditions. 
• The relative affinity of a target compound for the matrix components and for the coating 
proved to be a critical factor that determines the final Hct effect on SPME. 
• By using appropriate internal standards, variable SPME recoveries due to different Hct 







Many bioanalytical studies and clinical tests rely on the quantitative determination of small 
molecules in whole blood samples. Given the complexity of this type of matrix, developing simple 
analytical workflows that can provide satisfactory results while remaining compliant with health 
regulations can be a challenging undertaking. Whole blood is comprised of two main 
components: plasma and blood cells. Plasma has a relatively simpler composition than whole 
blood, which makes it a commonly-used matrix for many routine bioanalytical determinations, 
the most representative case of which being the therapeutic monitoring of multiple drugs. The 
second main component of whole blood is the cells, which can be classified into three main types: 
red blood cells (erythrocytes, ~96 %), white blood cells, and platelets [1]. Hematocrit (Hct) is a 
term that refers to the fraction of blood volume made up of red blood cells, and its typical values 
are within the ranges of 40 – 50% for men, and 36 – 44 % for women [2]. However, Hct levels can 
fall outside of these ranges in particular cases, such as individuals living at high altitudes, 
newborns, or anemic people [3]. Although plasma and serum are the specimens of choice for 
several standardized analytical procedures, the direct analysis of whole blood samples is required 
in certain instances (e.g. in forensic toxicology, in the determination of immunosuppressive 
drugs, among others). Hence, understanding and evaluating Hct’s effect on whole blood samples 
analysis should always be a matter of consideration.  
Numerous sample preparation methodologies for analyzing small compounds (<1500 Da) in 
whole blood samples using liquid chromatography coupled to mass spectrometry have been 
reported in the literature [4–11]. Among such approaches, liquid-liquid extraction (LLE) and 
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protein precipitation (PP)—which, in some cases is followed by cleaning steps involving online or 
offline solid-phase extraction—are perhaps the most commonly used strategies. For substances 
that display a high affinity for red blood cells, the use of additives that induce hemolysis and the 
release of compounds from erythrocyte membranes (e.g. zinc sulfate) have been reported as 
effective means of normalizing the sample matrix composition [12–14]. Nonetheless, the use of 
appropriate internal standards is always recommended in order to ensure satisfactory method 
accuracy and precision. Due to the highly-invasive nature of traditional blood collection, 
alternative blood micro sampling strategies have been garnering much interest. For instance, 
dried blood spots (DBS), which is a well-established sampling and whole-blood-analysis 
methodology, has been broadly reported in several applications due to its low invasiveness 
[7,9,15–18]. In DBS, a small drop of whole blood is placed on filter paper, allowed to dry, and 
subsequently analyzed by desorbing fixed-diameter discs punched out from the dried spots. Prior 
studies have found that Hct’s effect on DBS analysis is mostly associated with the variable 
spreading pattern that blood samples exhibit when spotted onto DBS cards [2,3,7]; the viscosity 
of blood samples is directly related to their Hct values, and samples with higher Hct values 
produce smaller spot radii. The best strategy for overcoming Hct’s impact in relation to variable 
blood spreading is to analyze whole spots of volumetrically-applied blood [3,7,19]. The 
incorporation of appropriate internal standards via spraying prior to DBS extraction has proven 
to be a feasible way of mitigating the variations related to matrix effects or recoveries [20,21]. 
Another absorptive-based approach recently introduced to overcome the Hct issues associated 
with DBS is volumetric absorptive microsampling (VAMS) [8], which uses an absorptive polymeric 
material immobilized on a pipette tip to collect fixed volumes of blood via wicking. Several studies 
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have demonstrated that VAMS devices are able to collect reproducible blood volumes 
independent of their Hct levels [8,22,23]. However, some issues with VAMS have also been 
reported, particularly in relation to bias in the determination of blood concentrations, low 
recoveries at high Hct levels, and interoperator variability [22,23]. Further evaluation of VAMS is 
still required as it is still a relatively new microsampling approach.   
Solid-phase microextraction (SPME) is a non-exhaustive extraction technique that uses a matrix-
compatible coating structure, which enables the analysis of complex samples, such as plasma and 
even whole blood. In fact, the literature contains several prior studies that document SPME’s 
usefulness as a sample preparation approach for such matrices prior to LC-MS or direct MS 
instrumental analysis [11,24–28]. Interestingly, SPME’s applicability is not only limited to ex vivo 
determinations; indeed, several studies have documented its suitability for in vivo blood analysis 
in different animal models [29–36]. In regards to the principle of SPME, it is worth mentioning 
that the extraction and pre-concentration of analytes occurs by directly exposing a defined 
amount of a biocompatible extraction phase to the sample matrix for a given period of time. The 
amount of analyte collected during the extraction process is proportional to the analyte’s 
concentration and depends on the analyte’s affinity for the biocompatible coating and for the 
sample matrix at the extraction conditions. Considering that the SPME matrix compatible coating 
is highly selective for small compounds and that a washing step is carried out after the extraction, 
the presence of proteins, salts, and other interferences that could affect the instrumental analysis 
is easily avoided. In regards to the extraction mechanism, it is worth emphasizing that, in SPME, 
the uptake of analytes from the sample media to the coating material happens via free analyte 
concentration [37]. Therefore, if we consider a complex system, such as blood samples, where 
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multiple co-existing phases can display an affinity for a given target compound, the amount of 
analyte extracted by the SPME probe will be correlated to the free concentration of analyte at 
the end of the extraction.  As a matter of fact, parameters such as lipophilicity, charge, molecular 
weight, diffusion coefficient, and structural moieties govern the distribution of any compound 
into different blood compartments [38]. Likewise, such parameters strongly determine the 
affinity that a target analyte exhibits for a particular SPME coating. In addition to the analyte’s 
physicochemical characteristics, there are other factors that play an important role in the 
microextraction process; for example, extraction time, extraction phase characteristics, 
temperature, and convection conditions all determine the final recovery provided by an SPME 
device. Given that red blood cells comprise a significant portion of a whole blood sample, this 
work aims to investigate how varying Hct levels affect the amount of analyte extracted by SPME 
devices. For this purpose, ten drugs with different polarities and physicochemical properties were 
chosen as model compounds, and blood samples with three different Hct levels (20%, 45%, and 
70 %) were selected as sample matrices. The effects of the coating type, sample convection, and 
extraction time were also taken into consideration.   
2. Experimental 
2.1. Materials and supplies 
Methamphetamine, stanozolol, codeine, codeine-d3, (±)11-nor-9-carboxy-Δ9-THC (THCCOOH), 
(±)11-nor-9-carboxy-Δ9-THC-d3 (THCCOOH-d3), oxycodone-d3, testosterone-d3, cannabidiol-d3 
and methadone-d3 standards were obtained from Cerilliant Corporation (Round Rock, TX, USA). 
Nikethamide, propranolol, metoprolol, clenbuterol, exemestane, and salbutamol were 
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purchased from Millipore Sigma (Oakville, ON, Canada), and salbutamol-d3 was purchased from 
CDN Isotopes (Pointe Claire, Quebec, Canada). Sodium chloride, potassium chloride, potassium 
phosphate monobasic, sodium phosphate dibasic, and formic acid were also purchased from 
Millipore Sigma (Oakville, ON, Canada). LC-MS grade acetonitrile, methanol, and water were 
obtained from Fischer Scientific. 
Biocompatible SPME fibres (MM-F) coated with a mixed-mode extraction phase (C18 and 
benzene sulfonic acid functionalities, 1.5 cm coating length, 45 μm coating thickness, and a total 
diameter of 300 µm) were generously provided by Millipore Sigma (Bellefonte, PA, USA). SPME 
devices prepared on a plastic support with a hydrophilic lipophilic balanced (HLB) extraction 
phase (HLB-D) (2 cm coating length, 150 µm coating thickness, and 2 mm total diameter) were 
made as described in [25].  
Blood samples were purchased from Bioreclamation IVT (Westbury, New York, USA). These 
samples were from healthy donors (with K2-EDTA as anticoagulant), and had Hct levels that had 
been adjusted to 20%, 45%, and 70%.  
2.2. Working solutions 
A stock methanolic solution (20 µg mL-1) containing all analytes (nikethamide, salbutamol, 
codeine, metoprolol, methamphetamine, clenbuterol, exemestane, propranolol, stanozolol and 
THCCOOH) was prepared and further dilution was done as required. A stock solution (8 µg mL-1) 
containing different deuterated compounds as internal standards was prepared in methanol. 
2.3. SPME procedure 
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Prior to the experiments, the blood samples with adjusted Hct content were spiked with stock 
methanolic solutions containing all the analytes, while ensuring that the organic solvent content 
was kept below 1% in all cases. For the construction of the calibration curves, the spiked blood 
samples were pre-incubated for at least 1 hour at constant agitation; for the determination of 
the extraction time profiles, blood samples incubation was allowed overnight. Before the 
extractions, MM-F and HLB-D were first pre-conditioned in a 1:1 (v/v) methanol:water solution 
for 30 min using vortex agitation at 1500 rpm. Subsequently, all devices were rinsed in ultrapure 
water for 10 s to remove any remaining organic solvent from the coating surface. In order to 
guarantee a stable sample pH (close to physiological pH) over the entire extraction process, 1080 
µL of spiked blood aliquots were mixed with 120 µL of 1 M phosphate buffer adjusted at a pH of 
7. Furthermore, 15 µL of internal standard solution were added to the samples used for the 
calibration curve experiments. The extractions were then carried out by immersing both types of 
SPME devices into the sample matrix for a pre-set period of time at constant agitation conditions. 
To construct the calibration curves, the extraction time was set at 90 min, the calibration range 
was set between 5 and 100 ng mL-1 for all target analyte, and four calibration curve replicates 
were constructed on two consecutive days. Time points of 15, 30, 60, 90, 120 and 180 min were 
selected for the extraction time profiles, and all the extractions were conducted in triplicates. 
The agitation parameters were set as follows: vortex agitation was set at 1500 rpm for the HLB-
D, and orbital shaking agitation was set at 400 rpm for the MM-F. Once the extraction step was 
completed, three consecutive rinsing steps in water (5 s each) were performed following the 
procedure reported by Reyes-Garces et al [25]. Finally, desorption of the devices was carried out 
for 20 min at 1500 rpm in 300 and 600 µL of desorption solution (4:1 methanol:acetonitrile) for 
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MM-F and HLB-D, respectively. To determine the amount of analyte extracted by the SPME 
devices in each experiment, an instrumental calibration curve (from 0.1 to 150 ng mL-1) was 
prepared using the same solvent composition that was used for the desorption solution. 
2.4. LC-MS/MS conditions and data processing 
All the collected extracts and the instrumental calibration curve were run using the LC-MS/MS 
conditions reported in [25]. Briefly, the LC-MS/MS system was comprised of an Accela 
autosampler, an Accela pump, and a TSQ vantage triple quadrupole mass spectrometer with a 
heated electrospray ionization source operating in positive mode (Thermo Scientific, San Jose, 
USA). Chromatographic separation was attained using a Kinetex pentafluorophenyl core shell 
column (1.7 µm, 2.1 mm x 10 mm) that had been connected to a PFP security guard ultracartridge 
(Phenomenex, Torrance, CA, USA), and LC separation was achieved using a mobile phase system 
consisting of 0.1% formic acid (A), acetonitrile with 0.1 % formic acid (B), and methanol with 0.1% 
formic acid (C). The gradient elution conditions were set as follows: A, B, and C were held at 90%, 
5%, and 5 %, respectively, for 0.5 min; B and C were then increased linearly to 50 % over the 
course of 6.5 min; C was then increased to 75 % and B was decreased to 25% over the course of 
5 min and held for 3.5 min. Finally, the column was kept at the initial gradient composition for 2 
min. The column temperature was kept at 35 ˚C, the total run time was 17.5 min, and the column 
flow was set at 0.3 mL min-1. Samples were stored in the autosampler at 5 ˚C, and the injection 
volume was 10 µL. MS analysis was conducted using selective reaction monitoring (SRM) mode, 
and the conditions of each compound were optimized by directly infusing the standards. Table 1 
summarizes information corresponding to SRM transitions of the model compounds The 
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following transitions were selected for the deuterated compounds that were employed as 
internal standards: salbutamol-d3: 243.16 151.12; codeine-d3: 303.15 165.10; oxycodone-
d3: 319.12  259.15; methadone-d3: 313.21  105.10; testosterone-d3: 292.25  97.14; and 
THCCOOH-d3: 348.16  302.28. Other parameters were set as follows: spray voltage = 1300 V; 
vaporizer temperature = 275˚C; sheath gas = 45 units; auxiliary gas = 30 units; and capillary 
temperature = 280˚C.  
2.5. Data analysis 
Xcalibur software (2.0.7 SP1) was employed for data acquisition and processing. For the purpose 
of this study, the slopes of the calibration curves constructed for each compound with different 
Hct levels were statistically compared. Statistical analysis was carried out using one-way ANOVA, 





3. Results and discussion 
In order to elucidate the effect that various Hct levels can have on SPME recovery rates, an 
analyte’s affinity for the main blood components (aqueous phase, proteins, and red blood cells) 
should be taken into consideration. For this reason, analytes with distinct physicochemical 
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properties were selected for this work because they can be expected to display variable affinities 
for blood constituents (Table 1). In addition to using various model compounds, two 
experimental setups were employed: MM-F at 400 rpm and HLB-D at 1500 rpm. Although both 
types of SPME devices have been documented as being suitable and biocompatible for the 
analysis of whole blood samples [25,32,39], the attachment of macromolecules is usually 
observed in the case of MM-F under aggressive agitation conditions and long extraction times. 
Consequently, an orbital shaker operating at 400 rpm was chosen as the agitation setup for MM-
F extractions. In the case of HLB-D, satisfactory results for whole blood samples analysis were 
already found when using vortex agitation at 1500 rpm; therefore, the same parameters were 
kept [25]. Although high agitation speeds such as 1500 rpm are likely to induce lysis in red blood 
cells—and therefore changes in the Hct content during the extraction [40]—the main purpose of 
the evaluation was to assess the overall effect of different red blood cell contents on SPME 
extractions under typical experimental conditions. 
Table 2 presents the results corresponding to the calculated slopes for each of the model analytes 
in blood samples with different Hct levels as determined by the two different experimental 
setups. It is worth emphasizing that slope calculation was selected as parameter for investigating 
Hct effect because it is a well-accepted approach for assessing relative matrix effects [41]. As 
shown in Table 2, different outcomes were found depending on the analyte and the experimental 
conditions; therefore, in order to simplify things, we classified the observations into four different 
cases: no Hct effect at any of the experimental conditions (Case I), Hct effect only when MM-F 
were used (Case II), Hct effect in both MM-F and HLB-D experiments (Case III), and Hct effect 
when HLB-D were used (Case IV).  
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In the first case (Case I), no statistically significant Hct effect was observed for any of the study 
conditions (MM-F at 400 rpm and HLB-D at 1500 rpm). Interestingly, salbutamol, nikethamide, 
codeine, and methamphetamine, which are all characterized as being relatively polar and/or for 
having low protein-binding affinities, were categorized in this first group. In order to explain the 
obtained results, parameters such as the polarity and affinity of an analyte for the matrix 
components and the extraction phases should be taken into account. With regards to an analyte’s 
polarity, it is important to emphasize that highly-polar compounds typically display shorter 
equilibration times due to their low affinities for SPME coatings (low K values). This is confirmed 
by Equation 1, where the equilibration time in SPME is expressed as a function of the boundary 
layer thickness (𝛿𝛿𝑠𝑠 ), the distribution constant (K), the thickness of the SPME coating (L), the 
diffusion coefficient of the analyte in the sample matrix (𝐷𝐷𝑠𝑠), and the coating capacity (Г𝑚𝑚𝑚𝑚𝑚𝑚) 
[42]. 
𝑡𝑡𝑒𝑒𝑒𝑒 ≈ 𝑡𝑡95% =
𝛿𝛿𝑠𝑠𝐾𝐾𝐾𝐾
𝐷𝐷𝑠𝑠Г𝑚𝑚𝑚𝑚𝑚𝑚
         (1) 
In this context, it is worth mentioning that, when extractions are performed at conditions close 
to equilibrium, the amount of analyte collected is mostly determined by the analyte’s distribution 
constant. Conversely, when the extraction process is interrupted at an earlier stage, the diffusion 
of the analytes in the sample matrix plays a more important role. Since 90 min was chosen as the 
extraction time for the Hct effect assessment, it was relevant for the interpretation of the results 
to determine at what point of the extraction process the comparison was being conducted. As 
shown in Figure 1A, a relatively polar compound like salbutamol was close to reaching 
equilibrium after 90 min of extraction using MM-F at 400 rpm. This means that variations in the 
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analyte’s diffusivity due to differences in the matrix viscosity will not have an important effect on 
the analyte’s uptake. Moreover, as can be seen in the same plot, minimal differences were found 
in the profiles constructed at the three Hct levels. Considering salbutamol’s high polarity and low 
protein binding, variable levels of matrix constituents are not expected to greatly affect SPME 
recoveries as a result of decreasing the analyte’s free concentration. In the case of HLB-D, a 
slightly different situation was observed for the same compound. As can be seen in Figure 1B, 
although there is an overlap in the constructed time profiles for blood samples adjusted at 
different Hct levels, a plateau in the extracted amounts of salbutamol was not achieved, even 
after 180 min of extraction at high-speed agitation. These results can be explained based on HLB’s 
much higher affinity for polar analytes and the thicker HLB-D coatings that permit the extraction 
of much larger amounts of analyte. Under such experimental conditions, the stronger affinity 
that HLB-D displays for the target analytes—compared to the one exhibited by the matrix 
constituents—will contribute to lessening the differences that can occur in SPME recoveries due 
to variations in the matrix composition. It is also noteworthy that the convection parameters in 
the HLB-D experiments were significantly higher than those in the MM-F extractions. Faster 
agitation conditions allow for a decrease in the thickness of the boundary layer, which in turn 
accelerates the mass transfer process occurring from the sample matrix to the SPME coating. 
Given this principle, the combination of improved convection conditions and HLB-D’s strong 
extraction capacity will result in a reduced Hct effect in the extraction of analytes that do not 
show a specific affinity for erythrocytes. In the case of compounds such as methamphetamine 
and codeine, which are less polar than salbutamol and nikethamide but still meet the conditions 
to be classified as Case I, it is noteworthy that the slopes of the calibrations curves constructed 
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with MM-F showed higher RSD values (9.5% and 8%) than those obtained with HLB-D (1% and 
0.1%). In fact, when MM-F was used, the slopes for methamphetamine and codeine were 
statistically higher in blood samples adjusted at 20 % Hct than for blood samples adjusted at 70 
% Hct (methamphetamine (20% vs 70% Hct): one-sample t(6)=3.52, p-value<0.01; codeine (20% 
vs 70% Hct): one-sample t(6)=4.42, p<0.01). Since these compounds are slightly hydrophobic, and 
considering the fact that codeine binds to the red blood cell plasma membrane, the presence of 
variable levels of matrix components is likely to alter the concentration of analytes available for 
SPME extractions [43]. Interestingly, this effect becomes more pronounced when devices with 
weaker affinities and lower extraction capacities, such as MM-F, are employed for extraction. In 
light of the discussed results, it is clear that the affinity of target analytes for the coating and the 
matrix components has a highly-significant effect on the final SPME recoveries when analyzing 
blood samples with different Hct levels.  
In order to explain the experimental findings corresponding to Case II, the same rationale 
regarding various analytes’ affinities for coatings and for matrix constituents should be taken into 
consideration. As can be seen in Table 2, Case II analytes had different outcomes that were 
dependent on the SPME experimental parameters. On the one hand, a pronounced decrease in 
the slopes as a function of erythrocyte levels was observed in the experiments conducted with 
MM-F; on the other hand, the statistical comparison of the slopes showed no Hct effect for 
extractions carried out with HLB-D (propranolol: F(2,9)=0.232, p-value=0.80; metoprolol: 
F(2,9)=0.243, p-value=0.79; clenbuterol: F(2,9)=1.031, p-value=0.40). The lack of observed 
differences when HLB was used can be attributed to the high convection conditions, as well as 
the fact that, as was discussed in relation to Case I, HLB-D has a much higher affinity for the target 
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analytes than MM-F and matrix components. Moreover, since the Case II analytes are overall less 
polar than those in Case I, they can be expected to have a higher degree of interaction with matrix 
components (lower free concentrations) and larger K values, and therefore longer equilibration 
times (Equation 1). Figure 1C presents the extraction time profile constructed for propranolol 
using MM-F at 400 rpm. As can be seen, the recoveries corresponding to the profile in 20% Hct 
blood samples are considerably higher than those obtained for the other two Hct levels. This 
outcome can be explained based on the fact that higher concentrations of matrix components—
in this case, red blood cells—lead to lower concentrations of propranolol available for SPME 
extraction; thus, lower amounts of propranolol are collected at 70 % Hct. Given that MM-F lacks 
sufficient extraction capability for inducing the release of bound analytes in order to further 
enhance the extraction recoveries, such experimental conditions tend to exhibit a significant Hct 
effect. Moreover, taking into account that the extraction process is still close to the linear regime 
at 90 min, it is possible that differences in the analyte’s diffusivity as a function of matrix viscosity 
could be partly responsible for variations in the uptake rate [44]. Although equilibrium is far from 
being reached at 90 min in HLB-D (Figure 1D), its high affinity for propranolol and the high 
convection conditions largely mitigate any effect that variable Hct levels can have on the final 
recoveries. Indeed, HLB’s high capacity for adsorption is able to deplete the analyte’s free 
concentration and induce the release of bound analytes back to their free forms, thereby 
increasing the total recovery. While possible changes in the matrix composition due to vigorous 
agitation [40] should be considered when explaining the different recoveries obtained using the 
two experimental setups, the results that will be presented in the next case clearly indicate that 
red blood cells remain a significant compartment after 90 min of vortex agitation.  
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In the third case noted in this study (Case III), a similar Hct effect for both MM-F and HLB-D was 
found; that is, the amount of analyte extracted decreased in proportion to the blood erythrocyte 
levels. This particular behavior was observed for exemestane, a relatively non-polar steroidal 
compound (Figures 1E and 1F). As shown in Table 2, extractions conducted with both MM-F and 
HLB-D produced higher calibration curve slopes for 20% Hct blood samples than for the ones 
calculated at 70% (MM-F (20% vs 70% Hct): one-sample t(5)=7.25, p<0.01; HLB-D (20% vs 70% 
Hct): one-sample t(4)=3.37, p<0.05). In the case of MM-F, a more pronounced variation was 
observed in the slopes of the calibration curves constructed at the different Hct levels due to the 
previously described effects of lower coating affinity and slower agitation. To the best of our 
knowledge, there is no information in the literature regarding the partitioning of exemestane 
into red blood cells. In fact, stanozolol, another steroidal compound that was used as a model 
analyte in this study, did not exhibit the same Hct effect. In order to confirm that exemestane 
was being partitioned into the erythrocytes, the recoveries of extractions from 70% Hct blood 
samples and fully-hemolyzed 70% Hct blood samples were compared using HLB-D. Complete 
blood hemolysis was achieved by storing pre-spiked 70% Hct blood samples for two hours at -80 
°C (i.e. freeze and thaw). As shown in Figure 2, the recovery of exemestane increased by 
approximately 60% when extracted from hemolyzed blood; this confirms that this drug is being 
partitioned into the red blood cells. To verify that the changes observed in exemestane recoveries 
were due to blood hemolysis and not due to ionization effects (suppression/enhancement), 
absolute matrix effects were assessed in 70% Hct blood samples (hemolyzed and non-hemolyzed) 
according to the procedure proposed by by Matuszewski et al (Figure 3) [41]. Based on these 
results, it is evident that exemestane’s affinity for the matrix is much higher than that of other 
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model analytes categorized in the previous cases such that even pronounced differences are 
observed when HLB-D are used. Therefore, the use of an internal standard that displays the same 
affinity for red blood cells is crucial to ensuring the successful analysis of exemestane in blood 
samples obtained from different patients.  
Similar to Case II, two different trends that were dependent on the SPME experimental conditions 
were observed in Case IV. Interestingly, the model compounds that were categorized within this 
last case are highly lipophilic and capable of significant protein binding. The slopes for these 
analytes were significantly higher at 70% Hct content when the extractions were carried out using 
HLB-D at 1500 rpm (THCCOOH (20% vs 70% Hct): one-sample t(5)=-8.58, p<0.01; stanozolol (20% 
vs 70% Hct): one-sample t(6)=-4.89, p<0.01) (Table 2). On the contrary, no statistical differences 
in the slopes were observed for the calibration curves constructed with MM-F (THCCOOH: 
F(2,8)=1.371, p-value=0.31; stanozolol: F(2,9)=1.539, p-value=0.27). One of the model 
compounds that exhibited this behavior was THCCOOH, the main secondary metabolite of THC. 
THCCOOH is a considerably non-polar analyte (logP 6.38) with 92.0 ± 8.7% protein binding [45]. 
In addition, according to previous studies, THCCOOH’s distribution into red blood cells is 
restricted [45,46]. Based on this behavior, the concentration of THCCOOH in plasma will be 
significantly higher than its concentration in whole blood (blood-to-plasma ratio = 0.65)[45]. 
Therefore, if we take into account that the volume of plasma is substantially less at 70% Hct than 
at 20% and 45% Hct, we can anticipate that a higher free analyte concentration will be available 
for SPME extractions at 70% Hct than at the other two Hct levels. This trend is reflected in the 
slopes for THCCOOH that were obtained with HLB-D (Table 2), and in its extraction time profile 
(Figure 1H). A similar behavior was also observed in the slopes for stanozolol that were 
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constructed under the same conditions. Stanozolol is also known for being highly lipophilic (logP 
4.43), but, to the best of our knowledge, there have been no prior studies that have analyzed its 
distribution in different blood components. With respect to the results obtained using MM-F, we 
hypothesize that the concentration available for SPME extractions, the convection conditions, 
and the diffusion of analytes all played an important role in the final outcome. As can be seen in 
Figure 1G, the THCCOOH uptake in MM-F is still in its linear regime at 90 min due to the slow 
convection and the compound’s high affinity for the coating. Hence, the analytes’ diffusion has a 
more significant effect on the extraction process than it does in cases where extractions are 
closer to equilibrium. In addition, it is important to consider that the flux of analyte from the 
sample matrix towards the coating (or analyte uptake) is proportional to the concentration 
gradient between the coating surface and the sample. Since a higher concentration of analyte is 
available for SPME extractions at 70% Hct, a higher uptake rate can be expected due to the 
concentration gradient. Based on this information, the estimated slopes for MM-F represent a 
combination of both the variation in analyte diffusion at different sample viscosities, and the 
changes in analyte uptake rates due to the concentrations available for SPME extractions at 
different Hct levels.  
As has been discussed so far, the Hct effect in SPME is completely dependent on the analytes of 
interest, and different outcomes can be obtained by changing the experimental conditions. 
Parameters such as an analyte’s physicochemical properties (lipophilicity, molecular weight, 
diffusivity, etc), distribution constants, convection conditions, and, to some extent, sample 
viscocity are all important in determining how Hct differences affect SPME recoveries. 
Nevertheless, as in any other sample preparation approach, the use of internal standards 
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represents the best way to account for any matrix variability. Table 3 presents the slopes after 
internal standard correction for those cases where F>Fcrit. Among seven deuterated drugs tested 
as internal standards (please refer to section 2.1), only those able to provide acceptable 
corrections were selected. Unfortunately, none of the available deuterated standards exhibited 
the same affinity for red blood cells shown by exemestane; as such, we could not provide the 
corrected data for that compound.  As can be seen in Table 3, the RSD values corresponding to 
the corrected slopes of those analytes that were significantly affected by variable red blood cell 
content were rewarding. Interestingly, compounds that were not necessarily deuterated 
analogues of the target analytes were able to provide adequate correction. Several studies in 
which SPME was used to analyze multiple substances in biofluids have described the use of a 
small set of internal standards as a practical and cost-effective strategy for correcting all of the 
target analytes [24,25,47]. However, as has been noted above, the behavior of a given analyte in 
a specific matrix depends on several factors, and a proper assessment of an internal standard’s 
suitability at various Hct levels is required when dealing with real blood samples. Indeed, 
although a given internal standard can effectively correct for extraction variations in a single 
blood lot, this does not necessarily mean that the same internal standard will properly account 
for varying Hct content. 
Further investigation should be conducted into alternative strategies for overcoming the Hct 
effect observed in SPME. These strategies may focus on full red blood cell lysis via a combination 
of using additives (e.g. zinc sulfate or organic solvents) or freezing and the addition of appropriate 
internal standards, preferably deuterated analogues. In the case of in vivo blood sampling, special 
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attention should be given to the Hct effect when external calibration curves are used for 
quantitation, as no internal standard can be introduced into the samples. 
 
3. Conclusions 
In this study, the effect of varying levels of Hct on SPME recoveries was investigated by using 
distinct model compounds and two different experimental setups. As expected, the observed 
effect was dependent on the analyte’s characteristics and the extraction parameters. For 
instance, variable Hct levels did not show any effect on the recovery of polar compounds with 
low protein affinities (e.g. salbutamol) under any of the study conditions. However, the extraction 
of more hydrophobic analytes, such propranolol, was strongly affected by the red blood cell 
content only when MM-F was used at 400 rpm. Similarly, for compounds such as 
methamphetamine, codeine, propranolol, metoprolol and clenbuterol, the use of HLB-D with 
high convection conditions produced negligible differences in the SPME recoveries from blood 
samples adjusted at various Hct levels. This demonstrated that an analyte’s relative affinity for 
the matrix and the extraction phase is critical when matrices with varying compositions are 
analyzed. Other model analytes, such as exemestane and THCCOOH, exhibited a negative and 
positive correlation, respectively, between the SPME recoveries and the Hct content due to their 
opposite affinity for red blood cells. Lastly, despite variations in analyte recovery due to different 
erythrocyte contents, it was possible to correct for relative matrix effects by using appropriate 
internal standards. Overall, since each analyte can display different Hct effects, variable red blood 
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cell levels within the final experimental conditions should be always properly assessed when 
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Table 1. Model compounds with their corresponding physicochemical properties and MS/MS 
detection parameters. Analytes are listed in order of hydrophobicity. 
Compound 
SRM transition 
Collision energy, S-lenses 





179.10  108.10 















1.19 7 – 25  
Metoprolol 
268.14 116.15 
18, 94  MW: 267.36 
1.88 12  
Methamphetamine 
150.11 91.12 
19, 45  
MW: 149.24 
2.07 10 – 20  
Clenbuterol 
277.068  203.049 
15, 70  
MW: 276.08 











17, 89  
MW: 259.16 
3.48 > 90 
Stanozolol 










6.36 92.0 ± 8.7[45] 









Table 2. Slopes of the calibration curves constructed using blood samples with different Hct levels spiked with drugs at concentrations 
in the range between 5 and 100 ng mL-1 (no internal standard). 
Compound (case) 
Slopes (n=4)a (average ± standard deviation) 
MM-F, 400 rpm HLB-D, 1500 rpm 
20 % Hct 45 % Hct 70 % Hct RSD % b F c 20 % Hct 45 % Hct 70 % Hct RSD % b F c  
Salbutamol (I) 0.018 ± 0.003 0.016 ±0.006 0.017 ± 0.004 4.0 0.090  0.25 ± 0.02 0.24 ± 0.04 0.23 ± 0.02 3.0 0.230  
Nikethamide (I) 0.042 ± 0.004 0.044 ± 0.004 0.039 ± 0.004 6.6 0.017  0.71 ± 0.06 0.73 ± 0.11 0.75 ± 0.06 3.0 0.238  
Methamphetamine (I) 0.058 ± 0.005 0.053 ± 0.009 0.048 ± 0.003 9.5 2.865 0.55 ±0.04 0.54 ± 0.07 0.54 ± 0.04 1.0 0.022 
Codeine (I) 0.034 ± 0.002 0.030 ± 0.004 0.029 ± 0.002 8.0 3.090 0.69 ±0.06 0.69 ± 0.05 0.69 ± 0.07 0.1 3.41e-4 
Propranolol (II) 0.047 ± 0.002 0.036 ± 0.003 0.027 ± 0.003 26.0 61.138  0.56 ± 0.05 0.57 ± 0.06 0.58 ± 0.04 2.0 0.232  
Metoprolol (II) 0.077 ± 0.008 0.064 ± 0.008 0.053 ± 0.006 19.0 11.108 0.83 ± 0.08 0.85 ± 0.10 0.88 ± 0.08 3.0 0.243 
Clenbuterol (II) 0.072 ± 0.004 0.059 ± 0.005 0.045 ± 0.004 14.0 36.232 0.69 ± 0.04 0.70 ± 0.04 0.73 ± 0.05 3.0 1.031  
Exemestane (III) 0.034 ± 0.005 0.023 ± 0.001 0.013 ± 0.003 45.0 37.719 0.31 ± 0.05 0.28 ± 0.03 0.21 ± 0.03 20.0 7.597 
THCCOOH (IV)d 0.010 ± 0.002 0.011 ± 0.001 0.012 ± 0.001 9.6 1.370 0.026 ± 0.001 0.032 ± 0.006 0.036 ± 0.002 16.2 8.851 
Stanozolol (IV) 0.040 ± 0.006 0.036 ±0.003 0.034 ±0.004 7.7 1.539 0.047 ±0.004 0.053 ±0.006 0.066 ±0.007 18.0 11.865 
 
a Average slopes calculated from the equation y=mx+b, where y is the amount extracted in ng and x is the concentration spiked in 
blood. 
b inter-slope RSD estimated from the values obtained for each Hct level. 
c F crit = 4.256 (α=0.05), if F > F crit the null hypothesis that the three slopes are equal is rejected (one-way ANOVA). 




Table 3. Corrected calibration curve slopes for those cases where F>Fcrit. 
Compound (internal standard) 
 
Slopes (n=4)a (average ± standard deviation) 
20 % Hct 45 % Hct 70 % Hct RSD % Fb 
Propranolol, MM-F  
(Methadone-d3) 0.018 ± 0.002 0.019 ± 0.001 0.017 ± 0.001 5.4 2.538 
Metoprolol, MM-F 
(Methadone-d3) 0.0053 ± 0.0002 0.0054 ± 0.0002 0.0055 ± 0.0003 1.2 0.331 
Clenbuterol, MM-F 
(Methadone-d3) 0.024 ± 0.001 0.024 ± 0.001 0.023 ± 0.001 3.1 3.058 
THCCOOHb, HLB-D 




0.41 ± 0.06 0.42 ± 0.02 0.46 ± 0.03 5.9 1.653 
a Average slopes calculated from the equation y=mx+b, where y is the ratio area analyte/area 
internal standard and x is the concentration spiked in blood. 
b F crit = 4.256 (α=0.05), if F > F crit the null hypothesis that the three slopes are equal is rejected 
(one-way ANOVA). 












Figure 1. Extraction time profiles obtained at different experimental conditions for four 
representative analytes: salbutamol (a and b), propranolol (c and d), exemestane (e and f), 
THCCOOH (g and h). Plots on the left side summarize results for MM-F at 400 rpm, and plots on 
the right side summarize results for HLB-D at 1500 rpm. 
Figure 2. Relative recoveries obtained after extracting from 70% Hct blood samples (hemolyzed 
vs. non-hemolyzed) spiked at 100 ng mL-1. These experiments were conducted using HLB-D at 
1500 rpm and an extraction time of 90 min. 
Figure 3. Absolute matrix effects assessed in 70% Hct blood samples (hemolyzed and non-
hemolyzed). Extracts from blank blood samples obtained with HLB-D (90 min extraction at 1500 
rpm) were spiked with the model compounds at 50 ng mL-1, and their response was compared 
with the one from standards spiked in neat solvent at the same concentration level. Acceptable 
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